Table 2 Uni- and multivariable Cox proportional hazards analysis for H3 K27M-mt DMG in the training and validation cohorts.
From: A validated prognostic nomogram for patients with H3 K27M-mutant diffuse midline glioma
Predictor | Univariate Hazard Ratio | 95% CI | p value | Multivariate Hazard Ratio | 95% CI | p value |
|---|---|---|---|---|---|---|
Gender (male vs. female) | 1.106 | 0.734–1.667 | 0.628 | |||
Age (≥ 16 years vs. < 16 years) | 0.498 | 0.329–0.755 | 0.001 | 0.5621 | 0.363–0.870 | 0.010 |
Anatomic location (Infratentorial vs. Supratentorial) | 1.062 | 0.707–1.596 | 0.773 | |||
Extent of resection | ||||||
GTR versus Biopsy | 1.1019 | 0.441–2.755 | 0.836 | |||
STR versus Biopsy | 1.1481 | 0.488–2.701 | 0.752 | |||
PR versus Biopsy | 0.7385 | 0.296–1.842 | 0.516 | |||
Pre-op KPS | 0.964 | 0.952–0.976 | 1.07e−08 | 0.959 | 0.947–0.971 | 1.54e-10 |
Radiotherapy (yes vs. no) | 0.186 | 0.097–0.356 | 4.21e−07 | 0.250 | 0.103–0.603 | 0.002 |
TMZ chemotherapy (yes vs. no) | 0.235 | 0.135–0.408 | 2.82e−07 | 0.5378 | 0.270–1.072 | 0.078 |
ATRX expression (lost vs. intact) | 0.986 | 0.596–1.633 | 0.957 | |||
p53 positivity (positive vs. negative) | 0.979 | 0.515–1.860 | 0.947 | |||
Ki-67 expression | 8.966 | 2.276–35.330 | 0.002 | 6.4656 | 1.437–29.086 | 0.015 |
MGMT (methylated vs. unmethylated) | 0.649 | 0.351–1.199 | 0.168 | |||
